P2RX7 and neoplasm: Mechanistically, the activation of P2RX7 leads to an increase in IL-18 production in an NLRP3-dependent manner, which subsequently activates NK cells and CD4+ T cells to produce IFN-γ, thereby enhancing tumor immunogenicity 188.